Table 1 Summary of LOXL2 and FOS immunostaining of human OS.

From: Wnt signaling and Loxl2 promote aggressive osteosarcoma

Panel a

Osteosarcoma (n = 49)

Chondrosarcoma (n = 27)

 

FOS positive

FOS negative

 

FOS positive

FOS negative

 

Cases

% cases

Cases

% cases

P value

Cases

% cases

Cases

% cases

P value

Total

27/49

55%

22/49

45%

 

15/26

58%

11/26

42%

 

 LOXL2 positive

20/27

74%

3/22

14%

0.00002

14/15

93%

8/11

73%

0.165

 LOXL2 negative

7/27

26%

19/22

86%

 

1/15

7%

3/11

27%

 

Panel b

LOXL2 positive

LOXL2 negative

 

LOXL2 positive

LOXL2 negative

 

Cases

% cases

Cases

% cases

P value

Cases

% cases

Cases

% cases

P value

Total

23/49

47%

26/49

53%

 

24/27

89%

3/27

11%

 

 FOS positive

20/23

87%

7/26

27%

0.00002

14/24

58%

1/3

33%

0.165

 FOS negative

3/23

13%

19/26

73%

 

9/24

38%

2/3

67%

 

Localization of Loxl2

 Nuclear

3/23

13%

   

10/24

42%

   

 Cytoplasmic + ECM

8/23

34%

   

0/24

0%

   

 Nuclear + Cytoplasmic + ECM

12/23

52%

   

14/24

58%

   
  1. The table includes 49 Osteosarcoma (OS) and 27 Chondrosarcoma (CS) from the US Biomax TMA (OS802c). Semi-quantitative analysis of LOXL2 and FOS expression in OS and CS with the percentage of samples with positive or negative staining in each subgroup (see also Fig. 7a–d). Panel a: samples are divided into FOS-positive and -negative groups and further subdivided into LOXL2-positive and -negative subgroups. Panel b: samples are divided into LOXL2-positive and -negative groups and further subdivided into FOS-positive and -negative subgroups. The localization of the LOXL2 IHC signal is indicated. ECM extracellular matrix. P value is calculated using Fisher’s exact test.
Back to article page